Severe adverse cutaneous drug eruptions: epidemiological and clinical features

Abstract

This study underlines the polymorphous clinical presentation of ACDR and the importance of researching some severity markers, which have important practical implications.

Patterns and Outcomes of Cutaneous Adverse Drug Reactions in a Hospital Based Study

“…Comparing the incidence of CADRs by gender, we found our inference to be confl ic ng with some studies repor ng a female preponderance 14,15,16 and was in line with other studies with male preponderance. 3,17,18 This study showed male preponderance with male female ra o of 1.8.…”

“…Our study revealed 54.8 % cases of CADRs being in age group of 15 to 35 years and similar age groups were aff ected by CADRs in few other studies. 3,14,17,18 Literatures suggested maculopapular erup ons as the most frequent reac on pa ern 3,15,19,20 while according to our study SJS (35.7%) was the most common CADR, while maculopapular erup ons and erythroderma were second highest reac ons with 16.7% each. The reason behind this may be the management of less severe exanthematous drug reac ons in outpa ent basis.…”

“…In our study the latency was 2 -90 days with an average of 20.07days, this was similar to the latency of 3 to 60 days in Tunisia. 15 However, one study revealed the latency for SJS/TEN to be few hours to one week 3 where as in another study 71.3% of CADR cases had a latency of less than a week. 17 It was 2 -14 days in 80% cases in a North Indian study.…”

“…20 In another study, 5 out of 12 cases of TEN and 2 out of 3 cases of erythroderma succumbed. 15 Overall mortality of CADR in another study was 5.1%, which consisted of 2 mortali es of SJS/TEN and 3 of TEN. 10 Mortality rate was 15.6% among all cases; 9% in SJS and 26.7% in TEN in another study.…”

Morphological Pattern of Cutaneous Adverse Drug Reactions due to Antiepileptic Drugs in Eastern India

“…Most epidemiological studies analysed the occurrence of CADR in inpatients and revealed a wide variation in the prevalence rate which range from 0.36% to 12.2% [5][6][7][8][9]11]. Few studies explored the rate of CADRs seen by a hospital dermatology department; CADRs accounted for 1.38% of all referrals to university hospital department of dermatology in Denmark and 1.5 % of total dermatology consultations seen at a hospital in Tunisia [7,12]. HLA-B 1502 a known genetic marker for both carbamazepine and phenytoin induced CADR was reported to be present in 47 of 300 (15.7%) normal Malay controls, 5.7% of 300 normal chinese controls and in none of the 100 normal Indian controls, in a study of 21 carbamazepine induced TEN/ SJS in Malaysia [9,10].…”